News2021-07-23T23:29:34+00:00

News

7th Annual CAR-TCR Summit to Feature Presentation By Exacis Biotherapeutics CEO

September 18th, 2022|

Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Leveraging mRNA Based Gene Editing to Optimize Advancement of Safe and Cost-Effective IPSC Products” as part of the focus track on Innovations in Gene Engineering and Editing at the 7th Annual CAR-TCR Summit in Boston on September 19, 2022.

Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells

November 9th, 2021|

Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis' innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer. The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.

Go to Top